Who is sponsoring NCT05131737?

NCT05131737 is sponsored by University of Zurich.

What drugs are being tested in NCT05131737?

Interventions in NCT05131737: High altitude exposure, Low altitude exposure.

What condition does NCT05131737 study?

NCT05131737 studies High Altitude Pulmonary Hypertension.

Is NCT05131737 still recruiting?

NCT05131737 is currently completed. Last updated 11 May 2022.

Last reviewed 2022-05-11 · How we verify

NCT05131737

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Exercise Endurance Time on the 2nd Day at 2500 m High Altitude

Completed NA Last updated 11 May 2022

What this trial tests

NA trial testing High altitude exposure in High Altitude Pulmonary Hypertension in 28 participants. Completed in 15 April 2022.

Timeline

18 October 2021

Primary endpoint
15 April 2022

15 April 2022

Quick facts

Lead sponsor	University of Zurich
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	screening
Enrollment	28
Start date	18 October 2021
Primary completion	15 April 2022
Estimated completion	15 April 2022
Sites	1 location across Switzerland

Drugs / interventions tested

High altitude exposure
Low altitude exposure

Conditions studied

High Altitude Pulmonary Hypertension — all drugs for High Altitude Pulmonary Hypertension →

Sponsor

University of Zurich

Who can join

18 and older, any sex, with High Altitude Pulmonary Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The impact of a sojourn at 2500 m of high altitude for 26-30 h on constant work-rate exercise test time in patients with precapillary pulmonary hypertension

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for High Altitude Pulmonary Hypertension

Currently open trials in the same condition.

NCT06852924 — Inhaled Nitric Oxide for High Amplitude Pulmonary Edema (HAPE) · NA · recruiting

Other University of Zurich trials

Trials by the same sponsor.

NCT07485699 — Soy Processing and Food Allergy · NA · not yet recruiting
NCT07516912 — Evaluation of Free STI Testing Pilot Projects in Lucerne and Zurich, Switzerland · not yet recruiting
NCT07473115 — Individualized Analgesia in the Intensive Care Unit With a New Pain Assessment Bundle and Protocolized Analgesia Adjustm · not yet recruiting
NCT07524023 — Emotional-distress-based Integrated Care Programme in Patients With Stable COPD · NA · recruiting
NCT06481982 — Value of Advanced MRI Techniques in the Assessment of Endometriosis · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05131737 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Zurich
Last refreshed: 11 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05131737.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing